1. Home
  2. RYTM vs FUL Comparison

RYTM vs FUL Comparison

Compare RYTM & FUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • FUL
  • Stock Information
  • Founded
  • RYTM 2008
  • FUL 1887
  • Country
  • RYTM United States
  • FUL United States
  • Employees
  • RYTM N/A
  • FUL N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • FUL Home Furnishings
  • Sector
  • RYTM Health Care
  • FUL Industrials
  • Exchange
  • RYTM Nasdaq
  • FUL Nasdaq
  • Market Cap
  • RYTM 3.2B
  • FUL 3.1B
  • IPO Year
  • RYTM 2017
  • FUL N/A
  • Fundamental
  • Price
  • RYTM $58.16
  • FUL $51.78
  • Analyst Decision
  • RYTM Strong Buy
  • FUL Hold
  • Analyst Count
  • RYTM 12
  • FUL 5
  • Target Price
  • RYTM $73.58
  • FUL $70.00
  • AVG Volume (30 Days)
  • RYTM 795.0K
  • FUL 731.5K
  • Earning Date
  • RYTM 05-06-2025
  • FUL 03-26-2025
  • Dividend Yield
  • RYTM N/A
  • FUL 1.68%
  • EPS Growth
  • RYTM N/A
  • FUL N/A
  • EPS
  • RYTM N/A
  • FUL 1.99
  • Revenue
  • RYTM $130,126,000.00
  • FUL $3,546,980,000.00
  • Revenue This Year
  • RYTM $45.46
  • FUL N/A
  • Revenue Next Year
  • RYTM $63.04
  • FUL $3.79
  • P/E Ratio
  • RYTM N/A
  • FUL $26.67
  • Revenue Growth
  • RYTM 68.06
  • FUL 0.99
  • 52 Week Low
  • RYTM $35.17
  • FUL $47.56
  • 52 Week High
  • RYTM $68.58
  • FUL $87.67
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 48.62
  • FUL 42.12
  • Support Level
  • RYTM $45.91
  • FUL $47.56
  • Resistance Level
  • RYTM $63.11
  • FUL $54.23
  • Average True Range (ATR)
  • RYTM 3.46
  • FUL 2.84
  • MACD
  • RYTM 0.29
  • FUL -0.26
  • Stochastic Oscillator
  • RYTM 36.33
  • FUL 33.43

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About FUL H. B. Fuller Company

H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. It generates the maximum revenue from hygiene, health and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based and solvent-based products for applications in various markets, including packaging , converting, nonwoven and hygiene (disposable diapers, feminine care and medical garments) and health and beauty. The company generates around half of its revenue in the United States.

Share on Social Networks: